A CASE OF NEUROSARCOIDOSIS SUCCESSFULLY TREATED WITH RITUXIMAB
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Involvement of the CNS is estimated in about 5% of patients with systemic sarcoidosis and less than half manifest isolated CNS disease.1
The diagnosis of definite neurosarcoidosis requires tissue biopsy demonstrating noncaseating granulomas in the absence of organisms or other causes.2 Corticosteroids are the mainstay of therapy and in one case series, over 70% of patients relapsed or progressed despite treatment with corticosteroids and oral immunosuppressant agents.3 Successful use of infliximab in cases of neurosarcoidosis has been described.4 Here we report a case of a patient who failed to respond to steroids and immune therapies and remained stable after treatment with B-cell-depleting therapy.
This being a case report of one patient without blinded observation for treatment, it is a Class IV study.
Case report.
A 50-year-old, right-handed white woman presented with clumsiness affecting the right upper extremity. Within a few days, the deficit progressed to complete loss of strength of the right upper extremity. MRI of the brain revealed multiple lesions in the bilateral hemispheres, some of which enhanced postcontrast (figure, A–C). CSF showed 3 cells, protein 47 mg/dL (normal 15–45), glucose 66 mg/dL (normal 40–70), immunoglobulin G index 0.51 (normal 0.28–0.66), synthesis rate 0.0 mg/day (normal 0–8), negative oligoclonal bands, and myelin basic protein 6.63 ng/mL (normal 0.07–4.1). CT chest, abdomen, and pelvis, bone scans, conventional …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Infliximab for the treatment of CNS sarcoidosisA multi-institutional seriesJeffrey M. Gelfand, Michael J. Bradshaw, Barney J. Stern et al.Neurology, October 13, 2017 -
Contemporary Issues in Neurologic Practice
MRI criteria for MS in patients with clinically isolated syndromesX. Montalban, M. Tintoré, J. Swanton et al.Neurology, January 06, 2010 -
Articles
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypesN. De Stefano, A. Giorgio, M. Battaglini et al.Neurology, June 07, 2010 -
Articles
HLA B*44Protective effects in MS susceptibility and MRI outcome measuresB.C. Healy, M. Liguori, D. Tran et al.Neurology, August 16, 2010